ROLE OF MULTIPLEX CYTOKINE ANALYSIS IN THE EVALUATION OF THE EFFICACY OF RITUXIMAB DURING TREATMENT FOR RHEUMATOID ARTHRITIS

ROLE OF MULTIPLEX CYTOKINE ANALYSIS IN THE EVALUATION OF THE EFFICACY OF RITUXIMAB DURING TREATMENT FOR RHEUMATOID ARTHRITIS

Along with its basic activity in removing B-lymphocytes, rituximab (RTM) causes depletion of a population of CD20+ T cells that can pro- duce a variety of immunoregulatory and proinflammatory cytokines and chemokines. Objective: to define a role of multiplex cytokine analysis in the evaluation of th...

Full description

Saved in:

Bibliographic Details
Main Authors:	A. A. Novikov, E. N. Aleksandrova, T. V. Popkova, O. G. Lineva, A. S. Avdeyeva, D. S. Novikova, G. Kh. Kuzikyants, G. V. Lukina, Ya. A. Sigidin, A. V. Karaulov, S. N. Bykovskaya, E. L. Nasonov
Format:	Article
Language:	Russian
Published:	IMA PRESS LLC 2011-06-01
Series:	Научно-практическая ревматология
Subjects:	rheumatoid arthritis rituximab cytokines multiplex analysis
Online Access:	https://rsp.mediar-press.net/rsp/article/view/1293
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

EFFECT OF RITUXIMAB ON THE BLOOD CHOLESTEROL TRANSPORT SYSTEM IN PATIENTSWITH RHEUMATOID ARTHRITIS
by: Tatyana Valentinovna Popkova, et al.
Published: (2010-08-01)

Impact of rituximab therapy on endothelial function and other markers of atherosclerosisin patients with active rheumatoid arthritis
by: Aleksandr Vital'evich Volkov, et al.
Published: (2010-12-01)

Combination therapy for rheumatoid arthritis with rituximab and leflunomide(preliminary results of the Russian ARBITR Registry)
by: Evgeniy L'vovich Nasonov, et al.
Published: (2011-02-01)

THE RUSSIAN REGISTRY OF RITUXIMAB. ANALYSIS OF THE EFFICIENCY OF THERAPY AND THE FUNCTIONAL STATEOF PATIENTS WITH RHEUMATOID ARTHRITIS
by: Vera Nikolayevna Amirdzhanova, et al.
Published: (2010-08-01)

CHANGES IN HEART RATE, HEART RATE VARIABILITY AND QT INTERVAL IN WOMEN WITH RHEUMATOID ARTHRITIS DURING RITUXIMAB TREATMENT
by: D. S. Novikova, et al.
Published: (2014-06-01)

Evaluation of the clinical efficiency of tocilizumab versus rituximab therapy in patients with rheumatoid arthritis
by: Anastasia Sergeyevna Avdeyeva, et al.
Published: (2012-08-01)

THE CLINICAL AND IMMUNOLOGICAL EFFECTS OF ANTI-B-CELL THERAPY IN PATIENTS WITH RHEUMATOID ARTHRITIS
by: Elena Nikolayevna Aleksandrova, et al.
Published: (2012-02-01)

USE OF RITUXIMAB IN PATIENTS WITH LUPUS NEPHRITIS
by: Anna Vasilyevna Torgashina, et al.
Published: (2010-08-01)

RITUXIMAB THERAPY MONITORING IN PATIENTS WITH RHEUMATOID ARTHRITIS HROUGH PERIPHERAL BLOOD GENE EXPRESSION ANALYSIS
by: E. V. Chetina, et al.
Published: (2014-06-01)

Dynamics of the level of calprotectin in patients with rheumatoid arthritis during rituximab biosimilar (Acellbia “Biocad”) therapy
by: A. S. Avdeeva, et al.
Published: (2021-09-01)

Rituximab in the treatment of Graves’ disease and endocrine ophthalmopathy. Opportunities and limitations
by: T. S. Panevin, et al.
Published: (2023-10-01)

CYTOKINE PROFILE IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
by: Maria Eduardovna Tsanyan, et al.
Published: (2013-12-01)

USE OF RITUXIMAB IN PATIENTS WITH SYSTEMIC MANIFESTATIONS OF PRIMARY SJOGREN'S SYNDROME
by: O. A. Logvinenko, et al.
Published: (2014-12-01)

RITUXIMAB TREATMENT FOR INTERSTITIAL LUNG INJURY IN SCLERODERMA SYSTEMATICA
by: Lidia Petrovna Ananieva, et al.
Published: (2013-12-01)

TIME COURSE OF CHANGES IN THE SYNOVIAL FLUID LEVELS OF PROINFLAMMATORY CYTOKINES IN RHEUMATOID ATHRITIS PATIENTS DURING RITUXIMAB TREATMENT
by: A V Bezgin, et al.
Published: (2011-08-01)

The use of “Acellbia” – a biosimilar of rituximab in systemic sclerosis
by: L. P. Ananyeva, et al.
Published: (2023-08-01)

Changes of cytokine profile measures during the treatment of rheumatoid arthritis with rituximab biosimilar (Acellbia, BIOCAD) and the original drug (MabThera, F. Hoffmann-La Roche Ltd., Switzerland)
by: A. S. Avdeeva, et al.
Published: (2019-03-01)

Sequential therapy with rituximab and belimumab in patients with systemic lupus erythematosus
by: A. A. Mesnyankina, et al.
Published: (2020-11-01)

CYTOKINE LEVELS IN PATIENTS WITH RHEUMATOID ARTHRITIS: AN ASSOCIATION WITH LUNG INJURY
by: D. V. Bestaev, et al.
Published: (2014-09-01)

Use of rituximab in systemic lupus erythematosus in children: a review
by: A. N. Arefyeva
Published: (2019-11-01)

RITUXIMAB TREATMENT EFFICACY IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS REFRACTORY TO STANDARD THERAPY IN THE LONG-TERM FOLLOW-UP
by: M. E. Tsanyan, et al.
Published: (2014-06-01)

THE EFFICACY AND SAFETY OF RITUXIMAB BIOSIMILAR (ACELLBIA®) IN RHEUMATOID ARTHRITIS AS THE FIRST BIOLOGICAL AGENT: RESULTS OF PHASE III (ALTERRA) CLINICAL TRIAL
by: E. L. Nasonov, et al.
Published: (2017-09-01)

THE RESULTS OF A PHASE III COMPARATIVE CLINICAL TRIAL OF RITUXIMAB (ACELLBIA® AND MABTHERA®) IN RHEUMATOID ARTHRITIS (THE BIORA STUDY)
by: E. L. Nasonov, et al.
Published: (2016-12-01)

EXPERIENCE WITH RITUXIMAB IN PATIENTS WITH ANKYLOSING SPONDYLITIS
by: Mikhail Sergeyevich Protopopov, et al.
Published: (2013-02-01)

Evaluation of rituximab therapy in real clinical practice (according to the OREL registry of patients with rheumatoid arthritis
by: A. S. Avdeeva, et al.
Published: (2019-07-01)

Comparison of the efficacy and safety of the original rituximab and its biosimilar in routine clinical practice
by: D. A. Kusevich, et al.
Published: (2022-06-01)

EXPERIENCE OF RITUXIMAB USE IN A PATIENT WITH SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS
by: E. I. Alekseeva, et al.
Published: (2012-08-01)

The efficacy of therapy with rituximab (R-CHOP) in patients with diffuse large cells lymphoma
by: T. D. Lutskaya, et al.
Published: (2014-07-01)

Dynamics of clinical manifestations and cytokine concentrations in rheumatoid arthritis patients on tofacitinib therapy
by: N. A. Lapkina, et al.
Published: (2021-12-01)

Rituximab in the treatment of nodal Bcell marginal zone lymphoma, primary Sjogren’s syndrome and autoimmune hepatitis
by: O A Logvinenko, et al.
Published: (2008-10-01)

Relationship between laboratory biomarkers and ultrasonographic signs of inflammation in patients with rheumatoid arthritis treated with a rituximab biosimilar
by: A. S. Avdeeva, et al.
Published: (2022-06-01)

IMMUNOLOGICAL EFFECTS OF A RITUXIMAB BIOSIMILAR (ACELBIA, BIOCAD) IN PATIENTS WITH RHEUMATOID ARTHRITIS
by: A. S. Avdeeva, et al.
Published: (2018-11-01)

Ten-year experience with rituximab for induction and maintenance therapy in patients with ANCA-associated systemic vasculitis
by: T. V. Beketova, et al.
Published: (2020-03-01)

EXPERIENCE OF RITUXIMAB TREATMENT IN A PATIENT WITH JUVENILE SCLERODERMA
by: E. I. Alexeeva, et al.
Published: (2012-05-01)

Safety and tolerability of rituximab in the treatment of systemic sclerosis
by: L. A. Garzanova, et al.
Published: (2023-04-01)

Clinical efficacy of the rituximab biosimilar Acellbia® 600 mg in patients with active rheumatoid arthritis in clinical practice
by: D. A. Kusevich, et al.
Published: (2019-01-01)

Pharmacoeconomic analysis of rituximab and belimumab therapy in patients with systemic lupus erythematosus
by: D. A. Gerasimova, et al.
Published: (2024-10-01)

Combination of bendamustine and rituximab in the management of relapsed and refractory chronic lymphocytic leukemia: the results of retrospective study
by: S. V. Semochkin, et al.
Published: (2015-06-01)

Belimumab in the treatment of systemic lupus erythematosus: 20 years of basic research, 10 years of clinical practice
by: E. L. Nasonov, et al.
Published: (2021-09-01)

Evaluation of effectiveness of long-term therapy with Russian rituximab biosimilar in Sjogren’s disease in real clinical practice
by: B. D. Chaltsev, et al.
Published: (2025-07-01)